Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications

Susan Rosenthal, George P. Canellos, Jacqueline Whang-Peng, Harvey R. Gralnick

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Chronic granulocytic leukemia (CGL) terminates in a disease similar to acute leukemia. Except for a study indicating an increased response rate to the drugs, vincristine and prednisone, therapy of this terminal phase has been universally disappointing. We have studied the bone marrows and clinical courses of 67 patients in the terminal phase of CGL to discern if any parameters were associated with an increased response rate or survival. The results of this study indicate that patients who have a lymphoblastic morphology or hypodiploid cytogenetics in the terminal phase respond better to treatment with the combination of vincristine and prednisone than those with myeloblastic morphology or hyperdiploid cytogenetics. Response rate and survival are significantly increased in those with lymphoblastic morphology. Recognition of the heterogeneity of the terminal phase of CGL may dictate specific therapeutic modalities.

Original languageEnglish
Pages (from-to)542-547
Number of pages6
JournalThe American Journal of Medicine
Volume63
Issue number4
DOIs
Publication statusPublished - Jan 1 1977
Externally publishedYes

Fingerprint

Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic Phase
Vincristine
Prednisone
Cytogenetics
Survival Rate
Polyploidy
Leukemia
Therapeutics
Bone Marrow
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications. / Rosenthal, Susan; Canellos, George P.; Whang-Peng, Jacqueline; Gralnick, Harvey R.

In: The American Journal of Medicine, Vol. 63, No. 4, 01.01.1977, p. 542-547.

Research output: Contribution to journalArticle

Rosenthal, Susan ; Canellos, George P. ; Whang-Peng, Jacqueline ; Gralnick, Harvey R. / Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications. In: The American Journal of Medicine. 1977 ; Vol. 63, No. 4. pp. 542-547.
@article{2f3bc3cfd053479288a62bc5a2bff6ff,
title = "Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications",
abstract = "Chronic granulocytic leukemia (CGL) terminates in a disease similar to acute leukemia. Except for a study indicating an increased response rate to the drugs, vincristine and prednisone, therapy of this terminal phase has been universally disappointing. We have studied the bone marrows and clinical courses of 67 patients in the terminal phase of CGL to discern if any parameters were associated with an increased response rate or survival. The results of this study indicate that patients who have a lymphoblastic morphology or hypodiploid cytogenetics in the terminal phase respond better to treatment with the combination of vincristine and prednisone than those with myeloblastic morphology or hyperdiploid cytogenetics. Response rate and survival are significantly increased in those with lymphoblastic morphology. Recognition of the heterogeneity of the terminal phase of CGL may dictate specific therapeutic modalities.",
author = "Susan Rosenthal and Canellos, {George P.} and Jacqueline Whang-Peng and Gralnick, {Harvey R.}",
year = "1977",
month = "1",
day = "1",
doi = "10.1016/0002-9343(77)90199-1",
language = "English",
volume = "63",
pages = "542--547",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications

AU - Rosenthal, Susan

AU - Canellos, George P.

AU - Whang-Peng, Jacqueline

AU - Gralnick, Harvey R.

PY - 1977/1/1

Y1 - 1977/1/1

N2 - Chronic granulocytic leukemia (CGL) terminates in a disease similar to acute leukemia. Except for a study indicating an increased response rate to the drugs, vincristine and prednisone, therapy of this terminal phase has been universally disappointing. We have studied the bone marrows and clinical courses of 67 patients in the terminal phase of CGL to discern if any parameters were associated with an increased response rate or survival. The results of this study indicate that patients who have a lymphoblastic morphology or hypodiploid cytogenetics in the terminal phase respond better to treatment with the combination of vincristine and prednisone than those with myeloblastic morphology or hyperdiploid cytogenetics. Response rate and survival are significantly increased in those with lymphoblastic morphology. Recognition of the heterogeneity of the terminal phase of CGL may dictate specific therapeutic modalities.

AB - Chronic granulocytic leukemia (CGL) terminates in a disease similar to acute leukemia. Except for a study indicating an increased response rate to the drugs, vincristine and prednisone, therapy of this terminal phase has been universally disappointing. We have studied the bone marrows and clinical courses of 67 patients in the terminal phase of CGL to discern if any parameters were associated with an increased response rate or survival. The results of this study indicate that patients who have a lymphoblastic morphology or hypodiploid cytogenetics in the terminal phase respond better to treatment with the combination of vincristine and prednisone than those with myeloblastic morphology or hyperdiploid cytogenetics. Response rate and survival are significantly increased in those with lymphoblastic morphology. Recognition of the heterogeneity of the terminal phase of CGL may dictate specific therapeutic modalities.

UR - http://www.scopus.com/inward/record.url?scp=0017742864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017742864&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(77)90199-1

DO - 10.1016/0002-9343(77)90199-1

M3 - Article

C2 - 269664

AN - SCOPUS:0017742864

VL - 63

SP - 542

EP - 547

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 4

ER -